Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Tuebingen, DEU
Paul-Ehrlich-Str. 15
Tuebingen, 72076, DEU



immatics biotechnologies

immatics is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product can50 didates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 – and thus less than three years after the conclusion of the first round of funding totaling €14 million – the company successfully concluded an international clinical study on its product candidate IMA901 for combating renal cancer. Further product candidates, also consisting of peptide-based immuno55 therapeutic substances for cancer therapy, are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline.

Recent Milestones



immatics biotechnologies screenshot
Above: immatics biotechnologies
Uploaded: 3/11/10


  1. EDGAR [edit]
  2. immatics receives €40 million in second round of funding ( [edit]
  3. immatics raises €54 million to advance its late stage clinical therapeutic cancer vaccine portfolio ( [edit]
  4. immatics biotechnologies Closes €34M Series D Round ( [edit]
Edit This Page
Last Edited 11/22/13

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy